AUCKLAND, New Zealand (July 1, 2020)—Fisher & Paykel Healthcare Corporation Limited announced today that F&P Evora, a nasal mask for the treatment of obstructive sleep apnea (OSA) has received regulatory clearance for use in the United States.
F&P Evora is a compact nasal mask that sits comfortably under the nose. The mask features CapFit headgear, which is designed for patients to put on like a baseball cap in one simple and intuitive movement. In a clinical trial, 98% of participants described F&P Evora as “simple to take off and put on in the dark,” and 95% of respiratory therapists found the mask “simple to fit.”
Evora also features the next generation of Dynamic Support Technology comprising of a ‘floating’ seal, which sits inside stability wings. This technology allows for freedom of movement during sleep while keeping the mask comfortably in place.
“Evora offers OSA patients the performance benefits of a nasal mask, with the streamlined design and minimalism of a nasal pillow mask,” said Lewis Gradon, Managing Director and CEO of Fisher & Paykel Healthcare. “This is a revolutionary product that makes fitting the mask and educating the patient much easier. We’re excited to bring it to market.”
Visit fphcare.com/evoranasal for more information.
